Venetoclax in AML: aiming for "just right"
- PMID: 30606807
- DOI: VSports手机版 - 10.1182/blood-2018-11-883454
Venetoclax in AML: aiming for "just right"
VSports注册入口 - Conflict of interest statement
Conflict-of-interest disclosure: L. C. M VSports手机版. served as a consultant to Novartis, Celgene, Incyte, previously held stock in Pfizer, and receives research funding from Jazz Pharmaceuticals.
Comment on
-
"V体育平台登录" Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.Blood. 2019 Jan 3;133(1):7-17. doi: 10.1182/blood-2018-08-868752. Epub 2018 Oct 25. Blood. 2019. PMID: 30361262 Free PMC article.
"VSports app下载" Publication types
MeSH terms
- "V体育2025版" Actions
- V体育2025版 - Actions
Substances
- V体育2025版 - Actions
- "VSports" Actions
- Actions (V体育ios版)
LinkOut - more resources
Full Text Sources
"VSports在线直播" Medical

